<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913870</url>
  </required_header>
  <id_info>
    <org_study_id>21617</org_study_id>
    <nct_id>NCT04913870</nct_id>
  </id_info>
  <brief_title>Angiotensin Receptor Blockers in Aortic Stenosis</brief_title>
  <acronym>ARBAS</acronym>
  <official_title>Impact of Angiotensin Receptor Blockers in Aortic Stenosis - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on&#xD;
      mild-to-moderate aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies support the concept that activation of the renin-angiotensin system may be involved&#xD;
      in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. Furthermore&#xD;
      recent studies have shown that renin-angiotensin system medication may slow down aortic&#xD;
      stenosis progression rate and left ventricle remodeling.&#xD;
&#xD;
      Thus the present study is a randomized control trial to test the efficacy of the angiotensin&#xD;
      receptor blocker (ARB) to slow down aortic stenosis progression and left ventricular&#xD;
      remodeling/dysfunction in patients with mild-to-moderate aortic stenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the anatomic progression of aortic stenosis</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Aortic valve calcification (measured by MDCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak aortic jet velocity</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>peak aortic jet velocity (Echocardiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aortic valve area</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>Aortic valve area (Echocardiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular (LV) dimension</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>LV dimension (Echocardiography, MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular (LV) mass</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>LV mass (Echocardiography, MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular (LV) fibrosis</measure>
    <time_frame>Baseline, 2 years</time_frame>
    <description>LV Fibrosis (MRI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Angiotensin Receptor Blockers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angiotensin Receptor Blockers will be given orally once a day for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a matched placebo orally once a day for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin Receptor Blockers</intervention_name>
    <description>Angiotensin Receptor Blockers treatment for 2 years.</description>
    <arm_group_label>Angiotensin Receptor Blockers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administration for 2 years.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and &lt;4m/s)&#xD;
&#xD;
          -  Normal left ventricular ejection fraction (i.e. ≥50%)&#xD;
&#xD;
          -  Systolic blood pressure &gt;110 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure &gt;70 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than mild aortic or mitral regurgitation, or mitral stenosis&#xD;
&#xD;
          -  Current use or documented indication for renin-angiotensin system medication or&#xD;
             Aliskiren&#xD;
&#xD;
          -  Known allergy or intolerance to angiotensin II receptor blockers (ARBs)&#xD;
&#xD;
          -  Alzheimer, dementia or known non-compliant patient&#xD;
&#xD;
          -  Renal dysfunction (glomerular filtration rate &lt;30ml/min/1.73m2)&#xD;
&#xD;
          -  Chronic hyperkalemia&#xD;
&#xD;
          -  Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment&#xD;
&#xD;
          -  Newly diagnosed (&lt;2 months) or poorly controlled diabetes&#xD;
&#xD;
          -  Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent&#xD;
             myocardial infarction (&lt;3 months)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients unable to read, understand or sign research consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Annick Clavel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Annick Clavel, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2678</phone_ext>
    <email>Marie-Annick.Clavel@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veronic Tremblay, TM</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3710</phone_ext>
    <email>Veronic.Tremblay@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRIUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Annick Clavel, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2678</phone_ext>
      <email>Marie-Annick.Clavel@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Krystel Duplain</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3868</phone_ext>
      <email>krystel.duplain-bouffard@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Annick Clavel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Mulham, MD</last_name>
      <phone>+4560677621</phone>
      <email>Mulham.Ali2@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Jordi Sanchez Dahl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Mulham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</investigator_affiliation>
    <investigator_full_name>Marie-Annick Clavel</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Angiotensin II Receptor Blockers</keyword>
  <keyword>Left ventricular remodeling</keyword>
  <keyword>Valvular heart disease</keyword>
  <keyword>Aortic stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

